click enter text
full postview ep beat rais ex-u
biosimilar eros assumpt goe deep end
report financi result friday revenu in-
line consensu beat ep rais revenu guidanc
slightli well mid-point ep guidanc
addit rais quarterli dividend
worrisom develop howev new guidanc rate eros
intern humira biosimilar eros follow launch biosimilar
octob bit apples-to-orang call
declin prior guidanc declin across
two-year window partli expect abbv prior
guidanc longer accur would refresh us support
idea manag may continu over-estim resili
humira post loe inde happen lever pull
bodi report full analysi
addit detail us/eu drug
compani cover see recent initi report oct
trade fundament data
upsid target
factset/wolf research price
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
friday open
report result in-lin consensu revenu beat ep
slightli rais revenu ep guidanc
announc dividend increas second compani coverag
recent one
overal impress solid quarter eleph room remain humira biosimilar launch
eu octob ask updat guidanc like intenational eros came
higher figur talk aggress tender process eu someth
control yet understand nordic countri one made tender
us would seem creat problem shown countri around world
low will go price beg bear case end anoth exampl
pharma compani under-estim downsid larg franchis begin roll think gsk
advair sanofi lantu happen offset larger would one obviou lever
pull howev arguabl lot uncertainti alreadi captur abbv lowest-in-the-group price-to-earnings
multipl sought ask question clarifi long-term outlook
allow session
term sale ep exhibit
revenu report sale vs estim consensu
ep report non-gaap ep vs estim consensu
humira sale vs estim consensu estim remind eu
biosimilar enter market oct first quarter abbv financi result
reflect meaning biosimilar impact
inbruvica sale vs estim consensu
hcv sale vs estim consensu
venclexta sale vs estim consensu first quarter
report discret sale product make sens view given increasingli robust
outlook follow approv r/r cll base murano studi
rais financi guidanc exhibit
revenu slightli rais prior guidanc
ep rais guidanc vs prior mid-point
page
pipelin new news press releas
revenu decreas ep increas
revenu estim chang ep estim chang
depend year
ep compound-annual-growth-rate ep compound-annual-growth-rate increas slightli vs prior repres
peer averag growth peer average compound-annual-growth-rate
price target unchang repres unchang multipl new slightli
gener prepar remark note
expect strong ep growth doubl digit growth yet quantifi
despit eu biosimilar hcv moder increas invest pipelin etc wolf comment
model ep growth consensu model
ceo made flatter comment chase outgo cfo tremend career discuss
move eu next summer
us mid-singl digit price benefit quarter new citrat formul help degre
expect intenational sale us guidanc still
 see eu point biosimilar outlook note
two week launch earli idea price everi singl market discount
higher end scenario plan still within rang rang high
nordic tender countri say unusu market surpris
remicad discount almost level repres intenational revenu consid
intenational market price lock still negoti idea
stand fluid need anoth month two see discount settl
price discount come approx percentag point higher would expect prior
page
intenational eros guidanc caution lock number think could still move
 eros blend across entir intenational bucket sale eu us
continu expect mid sd price increas humira say across entir book intenational sale
inde blend rate includ countri still biosimilar entrant us
perform primarili driven volum growth describ price us like
rate mayb low sd
 beyond risk greater price eros like saw continu say
biggest impact price/eros would launch would moder beyond
 clarifi time period new guidanc cover exactli eros across
two year period like prior guidanc say
say declin might grow bigger dramat
expect us
 quantifi aml indic venclexta gave gener market figur
incid etc quantifi sale potenti
 bleed class effect btki abbv view quit time bleed risk
on-target toxic across class manag side effect doesnt think differ
specif get around
expect sale
track line expect broad formulari coverag submit uf indic
put money sg rel support launch
 anyth call impact expir royalti agreement ad
factor
 maintain op guidanc note strong oper
margin growth base build describ come benefit om
come royalti expir still remain confid om guidanc
page
 magnitud settlement royalti humira compani patent settlement
forg would quantifi
 capit alloc updat regard pipelin product look asset bring product
time-frame look almost everyth small medium larger
 clarifi prior comment although biotech valuat come
still view fairli high
exhibit show compani report actual result vs estim consensu
exhibit abbvi result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit abbvi guidanc vs wr estim old new
page
oldnewoldnewtot marginabov margin interest tax guidancewr estim
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement oper expens foreign exchang incom expens outstand margin total profit profit profit incom growth oper
page
product revenu earli phase total
exhibit wr balanc sheet cash flow statement
page
flow statement incom intang chang oper asset flow oper activ busi net cash acquisit properti flow invest activ chang short-term issuanc lt lt debt leas treasuri flow financ activ fx cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock held paid-in comprhens sharehold liabil sharehold
